gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Plasminogen activator, tissue

Tissue Plasminogen Activator, t-PA, alteplase
This gene encodes tissue-type plasminogen activator, a secreted serine protease which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. Tissue-type plasminogen activator is synthesized as a single chain which is cleaved by plasmin to a two chain disulfide linked protein. This enzyme plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Plasminogen, HAD, AGE, CAN, PAI-1
Papers using Tissue Plasminogen Activator antibodies
Protease expression in the supernatant of Chinese Hamster Ovary cells grown in serum-free culture
Mahboudi Fereidoun et al., In Journal of Biomedicine and Biotechnology, 2002
... Rabbit polyclonal antibody to t-PA was supplied by Abcam (MA, USA) and goat ...
Papers on Tissue Plasminogen Activator
European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND.
Hacke et al., Heidelberg, Germany. In Int J Stroke, Feb 2016
RATIONALE AND HYPOTHESIS: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is an effective and approved therapy for acute ischemic stroke within 4.5 h of onset except for USA, Canada, Croatia, and Moldovia with a current 3 h label.
Decrease of Hyperintense Vessels on Fluid-Attenuated Inversion Recovery Predicts Good Outcome in t-PA Patients.
Kimura et al., Kurashiki, Japan. In Cerebrovasc Dis, Feb 2016
Here, we investigated serial changes to HV in patients with AIS who received tissue plasminogen activator (t-PA) therapy.
Management of Intrapleural Sepsis with Once Daily Use of Tissue Plasminogen Activator and Deoxyribonuclease.
Jantz et al., Gainesville, United States. In Respiration, Feb 2016
Twice daily intrapleural tissue plasminogen activator (tPA)/deoxyribonuclease (DNase) initiated at the time of diagnosis has been shown to significantly improve radiological outcomes and decrease the need for surgery.
Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro.
Bae et al., Kyŏngsan, South Korea. In Arch Pharm Res, Feb 2016
Furthermore, the effects of pelargonidin on the fibrin polymerization, platelet aggregation, and the ratio of plasminogen activator inhibitor-1 (PAI-1) to tissue plasminogen activator were determined.
Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke.
Chamorro et al., Barcelona, Spain. In Curr Neurol Neurosci Rep, Jan 2016
In experimental brain ischemia, exogenous UA and the thrombolytic agent alteplase exert additive neuroprotective effects when administered in combination.
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Smith et al., In Stroke, Jan 2016
PURPOSE: To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke.
Iodixanol Has a Favourable Fibrinolytic Profile Compared to Iohexol in Cardiac Patients Undergoing Elective Angiography: A Double-Blind, Randomized, Parallel Group Study.
Megson et al., Inverness, United Kingdom. In Plos One, Dec 2015
This study evaluated the impact of iohexol and iodixanol CA on fibrinolytic factors (tissue plasminogen activator [t-PA] and plasminogen activator inhibitor-1 [PAI-1]), as well as platelet-monocyte conjugates in cardiac patients undergoing elective angiography in a double-blind, randomised parallel group study.
The transient intraluminal filament middle cerebral artery occlusion model as a model of endovascular thrombectomy in stroke.
Buchan et al., Oxford, United Kingdom. In J Cereb Blood Flow Metab, Nov 2015
UNASSIGNED: The clinical relevance of the transient intraluminal filament model of middle cerebral artery occlusion (tMCAO) has been questioned due to distinct cerebral blood flow profiles upon reperfusion between tMCAO (abrupt reperfusion) and alteplase treatment (gradual reperfusion), resulting in differing pathophysiologies.
Alteplase for the Treatment of Pulmonary Embolism: A Review.
Paciullo et al., Atlanta, United States. In Adv Emerg Nurs J, Oct 2015
Alteplase is a fibrinolytic that is indicated for the treatment of pulmonary embolism in intermediate- and high-risk patients.
Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke.
Davis et al., Melbourne, Australia. In Lancet Neurol, Aug 2015
In most patients, thrombectomy was performed in addition to thrombolysis with intravenous alteplase, but benefits were also reported in patients ineligible for alteplase treatment.
Future directions of acute ischaemic stroke therapy.
Saver et al., Boston, United States. In Lancet Neurol, Jul 2015
For several years, the only therapy with proven efficacy for acute ischaemic stroke was alteplase, which is approved for use within 4·5 h after stroke onset in many countries, but only within 3 h in the USA.
Thrombectomy within 8 hours after symptom onset in ischemic stroke.
REVASCAT Trial Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Jul 2015
METHODS: During a 2-year period at four centers in Catalonia, Spain, we randomly assigned 206 patients who could be treated within 8 hours after the onset of symptoms of acute ischemic stroke to receive either medical therapy (including intravenous alteplase when eligible) and endovascular therapy with the Solitaire stent retriever (thrombectomy group) or medical therapy alone (control group).
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
SWIFT PRIME Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Jul 2015
BACKGROUND: Among patients with acute ischemic stroke due to occlusions in the proximal anterior intracranial circulation, less than 40% regain functional independence when treated with intravenous tissue plasminogen activator (t-PA) alone.
Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
IST-3 collaborative group, In Lancet Neurol, May 2015
BACKGROUND: Brain scans are essential to exclude haemorrhage in patients with suspected acute ischaemic stroke before treatment with alteplase.
Improvement of Psychotic Symptoms and the Role of Tissue Plasminogen Activator.
Nardi et al., Rio de Janeiro, Brazil. In Int J Mol Sci, 2014
Tissue plasminogen activator (tPA) mediates a number of processes that are pivotal for synaptogenesis and remodeling of synapses, including proteolysis of the brain extracellular matrix, degradation of adhesion molecules, activation of neurotrophins, and activation of the N-methyl-d-aspartate receptor.
Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase.
Hu et al., Penn Hills, United States. In J Am Soc Nephrol, 2012
activates the NF-kappaB pathway in macrophages through a signaling pathway involving annexin A2/CD11b-mediated integrin-linked kinase
Plasminogen activator inhibitor 1--insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence.
Shiio et al., San Antonio, United States. In Proc Natl Acad Sci U S A, 2012
The tissue-type plasminogen activator (t-PA)-plasminogen activator inhibitor-1 (PAI-1) system regulates the senescence-inducing activity of IGFBP3.
Cleavage of the NR2B subunit amino terminus of N-methyl-D-aspartate (NMDA) receptor by tissue plasminogen activator: identification of the cleavage site and characterization of ifenprodil and glycine affinities on truncated NMDA receptor.
Low et al., Houston, United States. In J Biol Chem, 2012
NR2B as a novel proteolytic substrate of tPA, where tPA may directly interact with NR2B subunits leading to a change in pharmacological properties of NR2B-containing NMDA receptors.
Tissue plasminogen activator and plasminogen activator inhibitor 1 contribute to sonic hedgehog-induced in vitro cerebral angiogenesis.
Zhang et al., Detroit, United States. In Plos One, 2011
The present study provides evidence that tPA and PAI-1 contribute to Shh-induced in vitro cerebral angiogenesis.
Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects.
Muniandy et al., Kuala Lumpur, Malaysia. In J Biomed Biotechnol, 2011
The aim of this study was to investigate the association of the PAI-1 4G/5G and tPA Alu-repeat I/D polymorphisms with T2DM in Malaysian subjects.
share on facebooktweetadd +1mail to friends